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Objectives The International Database on Ambulatory
Blood Pressure Monitoring (1993–1994) lacked a
prospective dimension. We are constructing a new
resource of longitudinal population studies to investigate
with great precision to what extent the ambulatory blood
pressure improves risk stratification.
Methods The acronym IDACO refers to the new
International Database of Ambulatory blood pressure in
relation to Cardiovascular Outcome. Eligible studies are
population based, have fatal as well as nonfatal outcomes
available for analysis, comply with ethical standards, and
have been previously published in peer-reviewed journals.
In a meta-analysis based on individual patient data,
composite and cause-specific cardiovascular events will be
related to various indexes derived by ambulatory blood
pressure monitoring. The analyses will be stratified by
cohort and adjusted for the conventional blood pressure
and other cardiovascular risk factors.
Results To date, the international database includes 7609
patients from four cohorts recruited in Copenhagen,
Denmark (n=2311), Noorderkempen, Belgium (n=2542),
Ohasama, Japan (n=1535), and Uppsala, Sweden
(n=1221). In these four cohorts, during a total of 69 295
person-years of follow-up (median 9.3 years), 1026
patients died and 929 participants experienced a fatal or
nonfatal cardiovascular event. Follow-up in five other
eligible cohorts, involving a total of 4027 participants,
is still in progress. We expect that this follow-up will be
completed by the end of 2007.
Conclusion The international database of ambulatory
blood pressure in relation to cardiovascular outcome will
provide a shared resource to investigate risk stratification
by ambulatory blood pressure monitoring to an extent not
possible in any earlier individual study. Blood Press Monit
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Introduction
In middle-aged and older individuals, hypertension is the
predominant cardiovascular risk factor. Any man still
normotensive at 50 years has a probability of over 90% to
become hypertensive during the remainder of his lifetime
[1]. Blood-pressure measurement is the basis for the
diagnosis and treatment of hypertension. Conventional
blood-pressure measurement by auscultation of the
Korotkoff sounds is fraught with potential sources of
error, which may arise in the patient, the observer, the
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sphygmomanometer, or in the overall application of the
technique [2]. Ambulatory monitoring allows the regis-
tration of blood pressure throughout the whole day in
patients engaged in their usual activities. Ambulatory
blood-pressure recordings have high reproducibility, are
not subject to digit preference, and avoid the transient
rise of a patient’s blood pressure in response to a medical
environment, the so-called white-coat effect [2,3].
Collaborative meta-analyses of individual patient data
constitute a powerful research tool to clarify the role of
cardiovascular risk factors in relation to total and cause-
specific mortality and morbidity, over and beyond the
prognostic information generated by single cohort studies
[4,5]. Earlier quantitative overviews published by the
Prospective Studies Collaboration [6] and by the Asian
Pacific Cohort Studies Collaboration [5] dramatically
refined our understanding of the risk conferred by the
conventionally measured blood pressure. Along similar
lines, the international database on ambulatory blood-
pressure monitoring [7] illustrated to what extent a meta-
analysis of individual patient data can contribute to our
understanding of the distribution [7,8] and the diurnal
profile [7,9] of ambulatory blood pressure across ethni-
cally diverse populations. This database constructed, in
1993–1994 [7], however, lacked a prospective dimension.
We therefore planned to build a shared new resource of
prospective studies conducted in the general population
with the objective of elucidating with great precision to
what extent ambulatory blood pressure improves risk
stratification over and beyond conventional blood pres-
sure. We chose IDACO as the acronym for the new
International Database of Ambulatory blood pressure in
relation to Cardiovascular Outcome.
Methods
Study eligibility
Eligible studies are those performed in random popula-
tion samples or those conducted in professional groups
representative of a community. At least one baseline
ambulatory blood-pressure recording and information on
subsequent fatal and nonfatal outcomes should be
available. Studies only qualify for inclusion in IDACO if
they have been ethically approved, if at enrolment
participants gave informed consent, and if they have
stood the test of publication in peer-reviewed journals.
Identification of studies
On the basis of our knowledge of the literature, we
identified 10 large-scale studies of ambulatory blood-
pressure monitoring: the Flemish project on environ-
ment, genes and health outcomes [10], the Copenhagen
monitoring of trend and determinants in cardiovascular
diseases health survey [11], the Uppsala longitudinal
study of adult men [12], the Ohasama study [13], the
JingNing population study [8], the Allied Irish Bank
study [14], the Montevideo study [15], the Leogra study
[16], the European project on genes in hypertension [17],
and the pressioni arteriose monitorate e loro associazioni
study [18]. An electronic search of the literature (in
English), using as search terms ‘ambulatory blood
pressure monitoring’ and ‘population’ did not reveal any
other eligible study in a general population. We will
repeat searches at 6-monthly intervals.
Data collection
The IDACO database is constructed and maintained at the
Studies Coordinating Centre in Leuven, Belgium.
While respecting medical confidentiality and national
legislations on the protection of privacy investigators will
provide information in electronic format on each partici-
pant’s baseline characteristics; anthropometrics, conven-
tionally measured blood pressure, one 24-h ambulatory
blood pressure recording, and cardiovascular risk factors.
With regard to follow-up, the information to be computer-
ized includes duration of follow-up, vital status at the end
of follow-up, and the incidence of fatal and nonfatal events.
After integration of the participants’ information into the
database, each investigator will receive detailed summary
statistics on his cohort. This process should help to
ensure that the common database incorporates correct
information and that there will be no conflicts between
data to be used in the meta-analysis and those already
reported by individual investigators in the literature
[10–13]. The IDACO database will be held in strict
confidence and will not be used in any publication
without the permission of the investigators who have
contributed data to a given analysis.
Conventional and ambulatory blood-pressure
measurement
The conventional blood pressure should be measured by
a standard mercury sphygmomanometer or a validated
automated device, using the appropriate cuff size, after
the patients have rested in the sitting [8,10,11,13–15,17]
or supine [12,16] position for at least 2 [13] to 5
[8,11,12,14,15,17] minutes. The average of the first two
conventional blood-pressure readings will be used for
analysis. If available, blood-pressure readings obtained in
the sitting position will be used. The thresholds proposed
by the joint national committee on the prevention,
detection, evaluation and treatment of high blood
pressure [19], and the European societies of hypertension
and cardiology [20] will be used for the classification of
participants according to their conventional blood pres-
sure. Patients on blood-pressure lowering drugs will be
classified as hypertensive.
Ambulatory blood-pressure recordings cover at least 24 h
and should be unedited or recorded with editing criteria
set to limits as wide as possible. The monitors should
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have been validated according to the guidelines of the
European Society of Hypertension [2] and their calibra-
tion should have been checked during the period of data
collection. For devices recording both auscultatory and
oscillometric readings, only the latter will be analyzed.
At the studies coordinating office, the same SAS macro
will process all individual ambulatory blood-pressure
recordings. Only the first 24 h of each recording will be
considered for analysis. Editing will be limited to the
exclusion of measurements that are marked as technically
inaccurate and those with a systolic blood pressure lower
than or equal to the diastolic pressure. Within-patient
averages of blood pressure over 24 h, daytime, and
nighttime will be weighted by the time interval between
consecutive readings. Recordings with less than 10
daytime readings and/or less than five nighttime readings
will not be considered for analysis. Daytime and night-
time will be defined using short fixed clock-time periods
[21], taking into account the daily pattern of activities of
the study participants. Short fixed clock-time intervals
eliminate the transition periods in the morning and
evening, during which the blood pressure changes rapidly
[7], and result in daytime and nighttime blood pressure
levels that are within 1–2 mmHg of the awake and asleep
levels [8,21]. In exploratory analyses, hourly blood-
pressure means will be plotted for each cohort to
ascertain that definitions of daytime and nighttime fit
the actually observed diurnal blood-pressure profile and
to find out whether sensitivity analyses should be
performed to exclude the white-coat window [2] or the
siesta period after lunch time.
The variability in the ambulatory blood pressure will be
modeled, using the 24-h, daytime and nighttime within-
patient standard deviations, the average real variability
[22], the day-to-night blood-pressure ratio [9], the day-
to-night blood-pressure difference [9], the blood-pres-
sure load [23], the runs-test [24], Fourier analysis [24],
cumulative sums [25], square wave modeling [21,26], the
morning surge in blood pressure [27,28], and the time
rate of variability [29]. Measures of blood-pressure
variability will always be analyzed, when accounting or
standardizing for the blood pressure level.
Other measurements
Data transfer will include detailed information on each
patient’s medical history, smoking and drinking habits,
and intake of medications. Smoking and drinking are the
current use of tobacco and alcohol. Body mass index will
be calculated as body weight in kilograms divided by
height in meters squared. Diabetes mellitus will be
defined as a self-reported diagnosis, a fasting or random
blood glucose level of at least 7.0 or 11.1 mmol per
liter (126 or 200 mg/dl) [30], respectively, or the use
of antidiabetic drugs. Previous cardiovascular disease
includes cardiac and cerebrovascular disorders and
peripheral vascular disease.
Definition of events
The primary endpoint consists of cardiovascular death,
nonfatal myocardial infarction, surgical and percutaneous
coronary revascularization, heart failure and stroke. If a
patient experienced more than one cardiovascular event,
only the first will be considered for analysis. Other
endpoints are all-cause mortality, cardiovascular mortality,
noncardiovascular mortality, stroke, cardiac disorders, and
coronary heart disease. Coronary events consist of death
from ischemic heart disease, sudden death, nonfatal
myocardial infarction, and coronary revascularization.
Cardiac complications include coronary events and fatal
and nonfatal heart failure. Fatal and nonfatal stroke do not
include transient ischemic attacks. If possible, stroke
events will be differentiated into ischemic and hemor-
rhagic stroke.
In terms of coding according to the International
Classification of Diseases (ICD), stroke will be defined
as ICD-8 or ICD-9 codes 430–434 or 436, or ICD-10
codes I60–I64. Myocardial infarction will be defined as
ICD-8 or ICD-9 code 410 or ICD-10 codes I21–I22, and
heart failure as ICD-8 4270, 4271, 4280, 4290, 5191 or
7824, or ICD-9 codes 429 or 5184, or ICD-10 codes I50 or
J81. Sudden death is ICD-8 code 4272 or 795, or ICD-9
code 4275 or 798, or ICD-10 codes I46 or R96. Peripheral
arterial disease corresponds with ICD-8 or ICD-9 codes
441–444, or ICD-10 codes I71–I74, and includes surgical
or peripheral revascularization procedures. In case ICD
codes are not available in the transferred data, the
definition of events as given by the investigators will be
accepted with reference to the publication on each cohort
in the peer-reviewed literature.
Statistical methods
For database management and statistical analysis, SAS
software version 9.1 or higher (SAS Institute, Cary, North
Carolina, USA) will be used.
All analyses will relate health outcomes to parameters
derived from ambulatory blood-pressure recordings both
in unadjusted and multivariate-adjusted analyses. In
exploratory analyses, incidence rates will be plotted by
quantiles of the ambulatory blood-pressure parameters,
but standardizing will be done by the direct method for
cohort. Next, the association between outcomes and the
indexes derived from ambulatory blood-pressure record-
ings will be further assessed, using the Cox proportional-
hazards model stratified by cohort. Adjusted analyses will
consider the following covariates measured at baseline:
sex, age, body mass index, smoking and drinking habits,
total serum cholesterol, diabetes mellitus, antihyperten-
sive drug treatment, and history of cardiovascular disease.
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Sensitivity analyses will be undertaken to confirm the
main conclusions of each analysis. As a general rule,
subgroup analyses will search for consistency in the
results according to sex, age group, antihypertensive
treatment at enrolment, and history of cardiovascular
disease. In addition, sensitivity analyses will also address
the question of whether the inclusion of one or more
cohorts biased the results in any direction.
Research objectives
Outcome-driven diagnostic thresholds for the
ambulatory blood pressure
Although blood pressure is continuously distributed,
clinicians need a diagnostic reference frame to interpret
ambulatory blood-pressure values and to classify patients.
Current guidelines propose operational thresholds for the
ambulatory blood pressure [2,19,20], but these limits rely
largely on the distribution of the ambulatory blood
pressure in normotensive reference populations or on
the regression of ambulatory on conventional blood
pressure. Generating outcome-driven diagnostic thresh-
olds for the ambulatory blood pressure was one of the
major objectives motivating this research consortium to
combine resources.
The relationship between cardiovascular outcomes and
blood pressure, irrespective of the technique of measure-
ment, is usually considered to be log-linear and contin-
uous [4]. For the usual blood pressure on conventional
measurement, the risk starts rising at levels of 115
mm Hg systolic and 75 mmHg diastolic [4]. According to
current guidelines [2,19,20], these are blood-pressure
values well within the normotensive range. One key issue
in the determination of outcome-based thresholds is
therefore the notion of the level of risk that is normal or
acceptable.
We chose to conform with the general consensus in
current guidelines [2,19,20]. We therefore planned to
determine levels of the ambulatory blood pressure
yielding risks equivalent to those associated with optimal
and normal blood pressure and hypertension on conven-
tional measurement. As an alternative approach, we will
also calculate the levels of the ambulatory blood pressure
resulting in a 5% or 10% overall cardiovascular risk over 10
years. The latter procedure does not involve any
assumption of risk associated with the conventional blood
pressure.
Ambulatory blood-pressure measurement to refine risk
stratification
In clinical practice, ambulatory blood-pressure monitoring
is a diagnostic instrument geared at refining risk
stratification. Along this line, IDACO will constitute a
powerful resource to address several issues related to the
prognostic significance of the ambulatory blood pressure.
The preliminary list of ambulatory blood-pressure in-
dexes, of which the predictive value will be investigated,
includes the following: (i) white-coat and masked
hypertension; (ii) the blood-pressure levels during day-
time and nighttime, and their ratio; (iii) measures of
diurnal blood-pressure variability, including the morning
surge in blood pressure [27,28] and the time rate of vari-
ability [29]; (iv) the ambulatory heart rate; and (v) pulse
pressure and the ambulatory arterial stiffness index
[31–33]. In addition, we will investigate to what extent
diabetes mellitus or a history of cardiovascular disease, as
compared with the absence of these conditions, impacts
on the prognostic accuracy of the ambulatory blood
pressure. All aforementioned analyses will explore
whether the indexes derived from ambulatory monitoring
are predictive over and above those derived from
conventional blood-pressure readings. Results from ana-
lyses, which require a dichotomization of the study
population, such as for instance those of white-coat and
masked hypertension or nighttime dipping status, will be
confirmed by analyses that include the exposure variables
as continuous measurements. Sample size permitting, it
is also our intention to construct risk charts similar to
those derived from Framingham [34] or the SCORE
system [35], but including the ambulatory blood pressure
as an additional risk factor.
Results
After contacting the investigators of 10 eligible studies,
nine studies [8,10–17], representing six European [10–
12,14,16,17], two Asian [8,13] and one South American
[15] cohort qualified for incorporation into the IDACO
database. Of these nine studies [8,10–17], four [10–13]
had outcome data available at the time of writing of this
manuscript and are, therefore, already included in the
database.
Cohorts with outcome data available in the IDACO
database
Currently, the IDACO database includes 7609 patients:
2311 residents of Copenhagen, Denmark [11]; 2542
residents of Noorderkempen, Belgium [10]; 1535 resi-
dents of Ohasama, Japan [13]; and 1221 men from
Uppsala, Sweden [12]. Table 1 lists the characteristics of
these patients by cohort. Overall, these four cohorts
include 3399 women (44.7%), 2220 smokers (29.5%),
3586 alcohol consumers (53.1%), 530 diabetic patients
(7.0%), and 640 participants with a previous history of
cardiovascular disease (8.4%). Median age (5th to 95th
percentile points) was 59 years (23–73). The conven-
tional blood pressures were obtained either at the
patient’s home (n= 2536) or at an examination center
(n= 4853), and were measured either in the sitting
(n= 6173) or the supine (n= 1216) position. Conven-
tional blood-pressure measurements were not available in
220 patients. Mean values in the remaining 7389 patients
were 131.3 ± 19.8 mmHg systolic and 79.0 ± 11.6 mmHg
diastolic. Of the 3314 hypertensive patients (43.6%),
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1640 (49.5%) were taking blood-pressure-lowering drugs.
The ambulatory blood pressure was not measured during
nighttime in 1623 of the 7609 patients. In addition, less
than 10 daytime readings and/or less than five nighttime
readings were available in 22 and 67 patients. The mean
24-h systolic and diastolic blood pressures in the
remaining 5897 patients averaged 126.1 ± 14.0 mmHg
for systolic and 73.6 ± 8.2 mmHg for diastolic.
Table 2 shows the number of events in each cohort
currently included in the database. Median follow-up
ranged from 8.3 years (5th to 95th percentile interval,
1.6–15.3 years) in Noorderkempen to 10.4 years (4.7–13.3
years) in Ohasama. In the overall study population, during
a total of 69 295 person-years of follow-up, 1026 patients
died and 929 participants experienced a fatal or nonfatal
cardiovascular event. The unadjusted incidence of fatal
and nonfatal cardiovascular complications averaged 13.4
events per thousand person-years, ranging from 5.5 to
31.4 events per thousand person-years in Noorderkempen
and Uppsala, respectively.
Eligible cohorts still awaiting completion of follow-up
Table 3 lists the baseline characteristics of the patients,
whose follow-up data are still being collected and who
were therefore not yet included in the database.
Discussion
The main objective of the IDACO project is to refine
current knowledge of ambulatory blood-pressure mon-
itoring as a diagnostic instrument in the stratification of
cardiovascular risk. Meta-analyses of individual patient
data are more resource-intensive and time-consuming
than meta-analyses based on summary statistics of
published reports. We, nevertheless, decided to perform
a meta-analysis based on individual patient data for
various reasons. First, in most cases, the statistics of
interest are not available from published reports. Second,
it has been shown that an aggregate-level analysis always
has less power than an investigation of individual patient
analysis [36]. Third, an individual patient meta-analysis
allows the use of the same statistical approach and quality
standards across studies. For instance, in IDACO, the
same SAS macro will process all individual ambulatory
blood-pressure recordings. Fourth, heterogeneity be-
tween cohorts can be better assessed. Heterogeneity
can be caused not only by differences in study design or
geographic location, but also by differences in the
characteristics of the individual patients. Finally, the
availability of individual patient data gives more flexibility
to extend or refine the planned analyses than an
aggregate level approach would do.
In IDACO, we opted not to combine cohorts of
hypertensive patients with patients randomly recruited
from the general population. The external validity and
generalizability of population-based results are obviously
larger than those emerging from cohorts of referred
hypertensive patients. In addition, we considered that, in
hypertensive patients, blood-pressure-lowering treatment
might be a confounder with too large an impact to adjust
Table 1 Baseline characteristics of cohorts with outcome data
Characteristic Copenhagen [11] Noorderkempen [10] Ohasama [13] Uppsala [12]
Number of patients 2311 2542 1535 1221
Women, no (%) 1130 (48.9) 1298 (51.1) 971 (63.3) 0
Age (years) 56.4 (10.2) 42.6 (17.0) 61.7 (10.7) 71.0 (0.6)
Body mass index (kg/m2)a 26.1 (4.1) 25.1 (4.5) 23.4 (3.1) 26.3 (3.4)
Weight (kg) 75.1 (14.1) 71.0 (14.7) 54.3 (9.3) 80.4 (11.5)
Height (cm) 169 (9) 168 (10) 152 (9) 175 (6)
Blood pressure (mmHg)
Conventional systolic 131.3 (19.3) 123.9 (17.0) 131.2 (18.5) 146.8 (18.5)
Conventional diastolic 83.4 (10.8) 75.3 (11.0) 74.1 (11.3) 83.8 (9.5)
24-h systolic 128.6 (12.8) 118.8 (11.1) 123.1 (13.2) 132.9 (15.6)
24-h diastolic 75.1 (8.5) 71.3 (7.4) 71.9 (7.7) 75.1 (7.7)
Daytimeb systolic 136.7 (13.8) 123.8 (11.0) 128.8 (14.3) 140.3 (16.3)
Daytimeb diastolic 80.6 (9.3) 76.1 (8.1) 75.9 (8.8) 79.8 (8.7)
Nighttimeb systolic 115.8 (14.0) 108.5 (12.2) 111.7 (14.8) 119.3 (18.6)
Nighttimeb diastolic 65.7 (9.1) 61.8 (8.2) 63.5 (8.3) 66.9 (9.0)
Serum cholesterol (mg/dl)c 239 (42) 208 (44) 193 (34) 225 (39)
Smokers, no (%) 998 (43.3) 692 (27.5) 285 (18.6) 245 (20.8)
Drinkers, no (%) 1983 (86.2) 645 (25.8) 278 (22.5) 680 (94.1)
Diabetes mellitus, no (%) 71 (3.1) 61 (2.4) 267 (17.4) 131 (10.8)
Cardiovascular disease, no (%) 137 (5.9) 188 (7.4) 98 (6.4) 217 (17.8)
Hypertension, no (%)d 1037 (44.9) 659 (26.0) 710 (46.3) 908 (74.5)
Antihypertensive treatment, no (%) 346 (15.0) 318 (12.6) 549 (35.8) 427 (35.3)
Data are mean (SD) or number of patients(%).
aBody mass index is body weight in kilograms divided by height in meters squared.
bDaytime ranged from 10:00 to 20:00 h in Europeans and from 08:00 to 18:00 h in Japanese. The corresponding nighttime intervals ranged from 00:00 to 06:00 h and
from 22:00 to 04:00 h, respectively.
cTo convert serum total cholesterol levels to millimoles per liter, divide by 38.67.
dHypertension is a conventional blood pressure of at least 140 mmHg systolic or 90 mmHg diastolic or the use of antihypertensive drugs.
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for. Indeed, in the older patients with isolated systolic
hypertension randomized to placebo (n= 393) in the
Systolic Hypertension in Europe trial [37], the 24-h,
daytime (10:00 to 20:00 h) and nighttime (from 00:00
to 06:00 h) systolic blood pressures all predicted the
incidence of cardiovascular complications, even after
further adjustment for office blood pressure. In contrast,
in the active-treatment group (n= 415), systolic blood
pressure at entry did not significantly predict cardiovas-
cular endpoints, regardless of the technique of blood-
pressure measurement [37]. In the four cohorts currently
included in the database, only one-fifth of the patients
Table 2 Incidence of events per cohort
Statistic Copenhagen [11] Noorderkempen [10] Ohasama [13] Uppsala [12] Four cohorts
Number of participants 2311 2542 1535 1221 7609
Median follow-up (years) 9.3 8.3 10.4 9.9 9.3
Total person-years 20 602 22 028 15 313 11 353 69 295
Fatal events
All 264 171 242 349 1026
Unknown cause 9 33 1 2 45
Noncardiovascular 150 79 155 193 577
Cardiovascular 105 59 86 154 404
Stroke 24 12 45 21 102
Ischemic heart disease 46 18 16 75 155
Sudden death 22 3 6 0 31
Heart failure y 14 9 4 y
Peripheral arterialdisease y 3 2 26 y
Other cardiovascular 13 9 8 28 116
Fatal plus nonfatal events
All cardiovasculara 272 121 179 357 929
Stroke 111 32 143 145 431
Cardiac events 173 86 31 207 497
Coronary eventsb 127 63 22 163 375
Myocardial infarction 97 31 12 134 274
Coronary revascularization 2 35 y y y
Heart failure 74 32 9 74 189
An ellipsis (y) indicates unavailable data.
aCardiovascular deaths plus stroke and cardiac events. Nonfatal events do not add up because composite end points include only the first event.
bMortality from coronary heart disease, including sudden death, plus myocardial infarction and coronary revascularization.
Table 3 Baseline characteristics of eligible cohorts still under follow-up
Characteristic Allied Irish Bank Study
[14]
EPOGH [17] JingNing [8] Leogra [16] Montevideo [15]
Number of patients 815 1106 716 265 1925
Women, no (%) 416 (51.0) 611 (55.2) 389 (54.3) 128 (48.3) 1142 (59.3)
Age (years) 36.3 (11.7) 38.4 (14.3) 48.0 (15.4) 71.1 (4.9) 50.0 (15.7)
Body mass index (kg/m2)a 24.1 (2.8) 25.4 (4.8) 22.4 (3.0) 27.5 (3.9) 26.9 (4.9)
Weight (kg) 68.2 (12.8) 72.3 (14.9) 54.6 (9.2) 74.0 (13.5) 73.4 (15.5)
Height (cm) 168 (9) 168 (9) 156 (8) 164 (8) 165 (10)
Blood pressure (mmHg)
Conventional systolic 119.2 (15.3) 128.9 (19.3) 131.2 (25.2) 173.4 (21.5) 129.2 (24.2)
Conventional diastolic 73.1 (10.0) 81.1 (12.0) 78.8 (13.1) 94.1 (10.0) 80.4 (12.1)
24-h systolic 118.3 (11.4) 120.5 (12.0) 122.8 (17.2) 142.7 (13.0) 120.7 (14.8)
24-h diastolic 72.4 (7.5) 72.8 (8.2) 78.1 (10.8) 79.0 (6.7) 75.6 (9.2)
Daytimeb systolic 124.7 (12.8) 126.9 (12.3) 128.0 (17.3) 149.1 (14.3) 123.9 (15.3)
Daytimeb diastolic 78.7 (8.6) 78.1 (8.3) 82.4 (11.0) 83.6 (7.9) 78.5 (9.9)
Nighttimeb systolic 106.4 (11.5) 109.3 (13.1) 113.7 (19.1) 131.3 (16.4) 111.5 (20.7)
Nighttimeb diastolic 61.9 (8.3) 63.5 (9.5) 70.9 (12.0) 71.9 (8.6) 65.2 (10.4)
Serum cholesterol (mg/dl)c Unavailable 198 (46) 191 (39) 233 (46) 221(44)
Smokers, no (%) 229 (28.1) 290 (26.2) 209 (29.2) 30 (11.3) 430 (22.3)
Drinkers, no (%) 658 (80.7) 394 (35.6) 387 (54.1) 215 (81.1) 548 (28.5)
Diabetes mellitus, no (%) 23 (2.8) 40 (3.6) 9 (1.3) 27 (10.2) 128 (6.6)
Cardiovascular disease, no (%) 26.3 (3.2) 72 (6.5) 6 (0.8) 61 (23.0) 132 (6.8)
Hypertension, no (%)d 0 368 (33.3) 267 (37.3) 263 (99.2) 762 (39.6)
Antihypertensive treatment, no (%) 0 183 (16.5) 97 (13.6) 74 (27.9) 350 (18.2)
Data are mean (SD) or number of patients (%). EPOGH indicates the European project on genes in hypertension, including participants recruited in Cracow, Poland
(n= 321), Novosibirsk, Russian Federation (n= 304), Mirano, Italy (n= 310), and Pilsen, the Czech Republic (n= 171).
aBody mass index is body weight in kilograms divided by height in meters squared.
bDaytime ranged from 08:00 to 18:00 h in Chinese and from 10:00 to 20:00 h in the other studies. The corresponding nighttime intervals ranged from 22:00 to 04:00 h
and from 00:00 to 06:00 h, respectively.
cTo convert serum total cholesterol levels to millimoles per liter, divide by 38.67.
dHypertension is a conventional blood pressure of at least 140 mmHg systolic or 90 mmHg diastolic or the use of antihypertensive drugs.
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were on antihypertensive drug treatment at baseline. All
analyses will be adjusted for antihypertensive drug
treatment. In addition, a sensitivity analysis in untreated
patients is planned to show indisputably whether or not
the results are confounded by antihypertensive drug
treatment.
In contrast to several other studies [18,38] relating
cardiovascular outcomes to the ambulatory blood pres-
sure, we will analyze both fatal and nonfatal outcomes.
The introduction of stroke units and the wide availability
of invasive coronary care and thrombolysis recently
reduced the case-fatality rate of most cardiovascular
complications of hypertension. Not accounting for non-
fatal events therefore limits the generalizability of some
reports [18,38].
IDACO will provide the means to test several hypotheses
that cannot be reliably analyzed in individual studies,
because of low event rates or short follow-up. An
important issue to be addressed is the prognostic
significance of white-coat hypertension and masked
hypertension. The interpretation of earlier studies on
white-coat and masked hypertension is difficult, because
of varying cut-off limits for hypertension on ambulatory
measurement, because of the confounding effect of
antihypertensive drug treatment in the hypertensive
cohorts [39–43], and/or because of the restriction of
outcome to a composite cardiovascular endpoint or
mortality [18,44]. Special attention will be paid to the
subgroup of patients with diabetes mellitus. As for
conventional blood pressure [20], more conservative
diagnostic thresholds for ambulatory blood pressure in
this high-risk subgroup might be warranted.
In conclusion, IDACO will provide a unique opportunity
to investigate several hypotheses that could not reliably
be studied from individual studies. The results of these
analyses might inform guidelines and be of help to
clinicians involved in the management of patients with
suspected or established hypertension.
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Appendix
IDACO centers and investigators
Belgium (Noorderkempen): R. Fagard, T. Kuznetsova, T.
Richart, J. A. Staessen, L. Thijs; China (JingNing): Y. Li,
J. G. Wang; the Czech Republic (Pilsen): J. Filipovsky´, J.
Seidlerova´, M. Ticha´; Denmark (Copenhagen): T. W.
Hansen, H. Ibsen, J. Jeppesen, S. Rasmussen, C Torp-
Pedersen; Italy (Padua): E. Casiglia, A. Pizzioli, V.
Tikhonoff; Ireland (Dublin): Eamon Dolan, Eoin O’Brien;
Japan (Ohasama): K. Asayama, J. Hashimoto, H. Hoshi, Y.
Imai, R. Inoue, M. Kikuya, H. Metoki, T. Obara, T.
Ohkubo, H. Satoh, K. Totsune; Poland (Cracow): M.
Cwynar, T. Grodzicki, K. Kawecka-Jaszcz, W. Lubaszews-
ki, A. Olszanecka, K. Stolarz, W. Wojciechowska; the
Russian Federation (Novosibirsk): T. Kuznetsova, S.
Malyutina, Y. Nikitin, E. Pello, G. Simonova, M. Voevoda;
Sweden (Uppsala): B. Andre´n, L. Berglund, K. Bjo¨rklund-
Bodega˚rd, L. Lind, B. Zethelius; Uruguay (Montevideo):
M. Bianchi, J. Boggia, V. Moreira, E. Sandoya, C.
Schettini, E. Schwedt, H. Senra.
Database management and coordination
T. W. Hansen, M. Kikuya, J. A. Staessen (Project
Coordinator), and L. Thijs (supervisor, database manage-
ment) constructed the IDACO database at the studies
coordinating centre in Leuven, Belgium.
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